Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01397604 · ClinicalTrials.gov registry record · Phase 1

The Effects of GLA on Human Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by Rockefeller University.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT01397604 is a Phase 1 study of Healthy Volunteers that has completed, run by Rockefeller University. The registered enrollment target is 32 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01397604, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The advent of vaccines contributed to major improvements in human morbidity and mortality due to infectious diseases such as polio, small pox, measles and diphtheria. However infectious diseases like HIV, malaria and tuberculosis continue to be major causes of death worldwide and conventional vaccine strategies have not been successful. The fundamental problem is that current protein based vaccines do not elicit the necessary T-cell immunity. Experimentally, adjuvants can be given in conjunction with a vaccine to activate and mature the dendritic cell (DC), which can then direct an immune response to enhance T-cell immunity. One family of potential adjuvants functions through the activation of Toll-like receptors (TLR) on the DC. Major gaps exist in our understanding of adjuvant effects in humans. We hypothesize that a synthetic adjuvant directed to activate TLR4 (GLA) will safely stimulate the innate immune system when administered subcutaneously (SC) or intramuscularly (IM). Importantly, in contrast to other adjuvant trials in which adjuvant is combined with an antigen or vaccine, GLA will be tested in isolation. This is because we anticipate the future administration of GLA with our dendritic cell targeted HIV vaccine. A DC-targeted vaccine cannot be given without an immune stimulating adjuvant due to potential risk of inducing immune tolerance. Therefore, in order to understand the specific contributions of GLA versus the DC-targeted vaccine, we need to understand the GLA effects in isolation. The safety and tolerability of 2 different formulations of GLA (GLA-SE vs. GLA-AF) administered by 3 different routes (SC, ID, IM) will be the major focus of this trial. The second focus will be characterizing the innate immune response by assessing systemic cytokine and chemokine levels and determining global gene regulation following GLA stimulation. The third focus will be on the cellular effects of GLA, specifically on blood monocytes and dendritic cells. Monocytes may

Conditions Studied

Interventions

  • DRUG GLA-AF
  • DRUG GLA-SE
  • OTHER Squalene

Study Locations (1)

New York

  • The Rockefeller University - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2011-07
Est. Completion 2013-03
Phase Phase 1

Sponsor

Rockefeller University

117 total trials

What the Registry Record Tells You About NCT01397604

The ClinicalTrials.gov registry entry for NCT01397604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which GLA-AF is the first listed.

NCT01397604 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01397604 about?

NCT01397604 is a clinical study titled "The Effects of GLA on Human Volunteers". The advent of vaccines contributed to major improvements in human morbidity and mortality due to infectious diseases such as polio, small pox, measles and diphtheria. However infectious diseases like HIV, malaria and tuberculosis continue to be major causes of death worldwide and conventional vaccin...

What is the current status of trial NCT01397604?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-07. Estimated completion is 2013-03.

What conditions does trial NCT01397604 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT01397604?

The interventions under investigation include: GLA-AF (DRUG), GLA-SE (DRUG), Squalene (OTHER).

Who is sponsoring clinical trial NCT01397604?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01397604 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.